Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Expert Answers to Questions on Contemporary Management of Hemophilia A

In this podcast episode, listen to Michael Callaghan, MD; Miguel A. Escobar, MD; and Rebecca Kruse-Jarres, MD, MPH, as they answer questions from a clinician audience on new and established approaches for managing hemophilia A in pediatric and adult patients.
Michael Callaghan, MD
Miguel A. Escobar, MD
person default
Rebecca Kruse-Jarres, MD, MPH
Released: February 4, 2021

In this episode, Michael Callaghan, MD; Miguel A. Escobar, MD; and Rebecca Kruse-Jarres, MD, MPH, answer questions from a clinician audience on topics related to hemophilia management including:

  • Maintaining long-term musculoskeletal health
  • Identifying patients most likely to benefit from pharmacokinetics-guided prophylaxis
  • Managing combination therapies in older patients with comorbidities
  • Youngest age at which patients can be considered for emicizumab
  • Development of resistance to emicizumab
  • Switching recombinant factor therapies
  • Using bypassing agents with emicizumab for breakthrough bleeds in patients with inhibitors
  • Potential clinical role of extending FVIII half-life with BIVV001
  • Considerations when dosing emicizumab monthly

Presenters:

Michael Callaghan, MD
Associate Professor
Department of Hematology
Wayne State University
Hematologist
Division of Hematology/Oncology
Children’s Hospital of Michigan
Detroit, Michigan

Miguel A. Escobar, MD
Professor of Medicine and Pediatrics
Department of Hematology
University of Texas Health Science Center
McGovern Medical School
Director
Gulf States Hemophilia and Thrombophilia Center
Houston, Texas

Rebecca Kruse-Jarres, MD, MPH
Professor
Department of Medicine
University of Washington
Executive/Medical Director
Washington Institute for Coagulation
Seattle, Washington

Acknowledgements

Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by educational grants from
Genentech, a member of the Roche Group
Sanofi Genzyme Corporation
Takeda Pharmaceutical Company Ltd

Related Content

On-demand Webcast updated with data from ASH 2020 with expert faculty discussing recent data on management of hemophilia A, presented by Clinical Care Options (CCO)

Miguel A. Escobar, MD
Program Director
Michael Callaghan, MD person default Rebecca Kruse-Jarres, MD, MPH
Physicians: maximum of 1.5 AMA PRA Category 1 Credits Released: February 25, 2021 Expired: February 24, 2022

Hanny Al-Samkari, MD; Sujit Sheth, MD; and Mark A. Schroeder, MD: top picks of nonmalignant hematology studies from ASH 2020 as reported by CCO

Hanny Al-Samkari, MD Mark A. Schroeder, MD Sujit Sheth, MD Released: February 24, 2021

From Clinical Care Options (CCO), expert answers to audience questions from 2 live meetings on contemporary management of hemophilia A

Michael Callaghan, MD Miguel A. Escobar, MD person default Rebecca Kruse-Jarres, MD, MPH Released: February 16, 2021

Review expert perspectives and insights on the most clinically relevant data on ITP, hemophilia, β-thalassemia, sickle cell disease, and GVHD presented at the Hematology 2020 annual meeting.

Hanny Al-Samkari, MD Mark A. Schroeder, MD Sujit Sheth, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: February 11, 2021 Expired: February 10, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue